Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Parvis Sadjadian
Observed names:
P Sadjadian,
P. Sadjadian,
Sadjadian, Parvis
Institutions:
University Hospitals of the Ruhr-University of Bochum,
LWL-Universitätsklinikum Bochum,
Johannes Wesling Klinikum Minden
Observed institutions:
Heidelberg University,
University Hospitals of the Ruhr-University of Bochum,
Helios Klinikum Emil von Behring,
University Hospital of Larissa,
LWL-Universitätsklinikum Bochum,
Johannes Wesling Klinikum Minden,
Technical University of Munich,
Ruhr University Bochum
show all 8
ORCID:
0000-0002-6380-6840
Observed ORCID:
0000-0002-6380-6840
OpenAlex ID:
A5049904099
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
2023
·
Srdan Verstovsek
, Aaron T Gerds
, et al.
·
The Lancet
·
233
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
2020
·
Frank Griesinger
, Wilfried Eberhardt
, et al.
·
Lung Cancer
·
101
PDF
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
2018
·
M. Thomas
, S. Ponce-Aix
, et al.
·
Annals of Oncology
·
84
PDF
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
2015
·
David F. Heigener
, Christian Schumann
, et al.
·
The Oncologist
·
84
PDF
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
2020
·
on behalf of the Vx-001-201 trial team
, Cesare Gridelli
, et al.
·
British Journal of Cancer
·
63
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy
2018
·
Martin Griesshammer
, Parvis Sadjadian
, et al.
·
Expert Review of Hematology
·
60
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
2017
·
M. Thomas
, P. Sadjadian
, et al.
·
Investigational New Drugs
·
56
PDF
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
2022
·
Marta Sobas
, Jean-Jacques Kiladjian
, et al.
·
Blood Advances
·
52
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
2018
·
Valerio De Stefano
, Alessandra Carobbio
, et al.
·
Blood Cancer Journal
·
40
PDF
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
2020
·
Parvis Sadjadian
, Kai Wille
, et al.
·
Cancers
·
38
PDF
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
2018
·
Kai Wille
, Parvis Sadjadian
, et al.
·
Annals of Hematology
·
36
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
2020
·
Karlo Huenerbein
, Parvis Sadjadian
, et al.
·
Annals of Hematology
·
32
PDF
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
2021
·
Rohit Sekhri
, Parvis Sadjadian
, et al.
·
Annals of Hematology
·
23
PDF
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
2020
·
Frank Stegelmann
, Kai Wille
, et al.
·
Leukemia
·
23
PDF
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
2025
·
Yan Beauverd
, Jean-Christophe Ianotto
, et al.
·
Leukemia
·
22
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
2017
·
Martin Griesshammer
, Parvis Sadjadian
·
Expert Opinion on Pharmacotherapy
·
22
Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera
2023
·
Yan Beauverd
, Jean-Christophe Ianotto
, et al.
·
Blood
·
20
Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
2023
·
Kai Wille
, Maja Brouka
, et al.
·
HemaSphere
·
20
Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety
2020
·
For the German Study Group MPN, GSG-MPN
, Lukas Schrickel
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
18
A review of hydroxyurea-related cutaneous adverse events
2021
·
Martin Griesshammer
, Kai Wille
, et al.
·
Expert Opinion on Drug Safety
·
16
Bleeding complications in bcr‐abl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients
2021
·
Kai Wille
, Karlo Huenerbein
, et al.
·
European Journal Of Haematology
·
14
PDF
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera
2021
·
Kai Wille
, Johannes Bernhardt
, et al.
·
European Journal Of Haematology
·
14
PDF
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
2023
·
Frank Griesinger
, Wilfried E.E. Eberhardt
, et al.
·
JTO Clinical and Research Reports
·
13
PDF
Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia
2024
·
Kai Wille
, Marvin Dumke
, et al.
·
European Journal Of Haematology
·
10
PDF
Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms
2023
·
Kai Wille
, Eva Deventer
, et al.
·
Hämostaseologie
·
8
PDF
Show more works
View as search
Works count:
53
Citation count:
1,138
H-index:
18
I10-index:
24
Year
Topic
Type